Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma kallikrein (Homo sapiens (Human)) | BDBM416879 (1-(3-(aminomethyl)phenyl)-N-(3-((3-cyanophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416882 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416884 (1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416885 (1-(3-(aminomethyl)phenyl)-N-(5-((3-(aminomethyl)ph...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416888 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-me...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416890 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439471 (US10633345, Compound 54e | US10633345, Compound 70...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416893 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416894 (1-(3-(aminomethyl)phenyl)-N-(5-((4-cyanophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416896 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416897 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416899 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416900 (1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416902 (1-(3-(aminomethyl)phenyl)-N-(3-((2-chlorophenyl)((...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416903 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416902 (1-(3-(aminomethyl)phenyl)-N-(3-((2-chlorophenyl)((...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416906 (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416908 (1-(3-(aminomethyl)phenyl)-N-(3-((2,4-dichloropheny...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416909 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439493 (US10633345, Compound 201f) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416912 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416775 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416773 (1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416775 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416773 (1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416843 (1-(3-(aminomethyl)phenyl)-N-(3-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416897 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416843 (1-(3-(aminomethyl)phenyl)-N-(3-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416897 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416721 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439471 (US10633345, Compound 54e | US10633345, Compound 70...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416721 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439471 (US10633345, Compound 54e | US10633345, Compound 70...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416930 (1-(3-(Aminomethyl)phenyl)-N-(3-((3-bromo-4-hydroxy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416725 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416909 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416933 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416725 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416909 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416936 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416770 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416903 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416939 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416770 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416903 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416942 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416751 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416906 (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416945 (US10329260, Compound 250c | US10633345, Compound 2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416751 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 302 total ) | Next | Last >> |